Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Reversible pulmonary artery hypertension in association with interferon-beta therapy for multiple sclerosis.
Patterns of Treatment Switching in Multiple Sclerosis Therapies in US Patients Active on Social Media: Application of Social Media Content Analysis to Health Outcomes Research.
Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Association of Immunotherapies With Outcomes in Relapsing-Remitting Multiple Sclerosis.
Treatment of multiple sclerosis with the pregnancy hormone estriol.
Gordon Research Conference on Myelin Biology and Pathobiology of Myelinating Glia
Gene expression analysis reveals functional pathways of glatiramer acetate activation.
PHENYTEK®* Capsules (extended phenytoin sodium capsules, USP)
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Regulation of prefrontal cortex myelination by the microbiota.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Extension CombiRx data show no benefit of combined MS drugs
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Isolation of Clostridium perfringens Type B in an Individual at First Clinical Presentation of Multiple Sclerosis Provides Clues for Environmental Triggers of the Disease.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Keystone Symposium: Multiple Sclerosis
Glatiramer Acetate and Nanny Proteins Restrict Access of the Multiple Sclerosis Autoantigen Myelin Basic Protein to the 26S Proteasome.

Pages